A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
admin Patients with advanced pancreatic adenocarcinoma who were treated with the company’s daily pill called daraxonrasib...
Health
Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target
A group of researchers led by Richard DiMarchi and Matthias Tschöp—two of the most decorated...
Morning Rounds: RFK Jr. Faces Congressional Scrutiny, Mental Health Parity Gaps, and the Future of Compounded Peptides.
Health Secretary Robert F. Kennedy Jr. is set to arrive on Capitol Hill today to...
CMS proposes rolling back breakthrough device payment flexibilities
The crux of the issue lies in the New Technology Add-on Payment (NTAP) program, a...
Morning Rounds: Navigating the Intersection of AI Diagnostics, Federal Law Enforcement, and the Future of Medical Training.
The landscape of modern medicine is currently being reshaped by a convergence of rapid technological...
Congress returns to a packed health care agenda
As the dust settles on this latest social media skirmish, the focus in Washington shifts...
A fluoride shortage for some U.S. water systemsÂ
The participants in this pilot program represent a "who’s who" of the digital health and...
FDA Issues Massive Warning to 2,200 Entities Over Missing Clinical Trial Results
In a bid toward greater transparency, the Food and Drug Administration sent reminder letters to...
Trump goes soft on insurance, and a medical underwriting chart
A few months ago, President Trump confidently declared to a room of reporters and a...
Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
Patients enrolled in the trial who received the daily pill, known scientifically as a multi-RAS...
